Neurohk s.r.o.

Chocen 27 trials 11 recruiting

27 Registered trials

11 Currently recruiting

Organisation

Neurohk s.r.o.

Location

Chocen, Czechia

Identifier

ORG-100043417

Address

Smetanova 830, 565 01, Czechia

Departments

---
#203003
Chronic pain
n/a
NA
NEUROHK s.r.o.
Neurological Outpatient Clinic
Neurologie
Neurology
Neurology Clinic
Ortopedic

Clinical trials at this site (27)

Search interface

A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease Pending

2025-521113-13-00 Early Parkinson’s Disease 10
An Open-Label Study of ML-007C-MA in Adults with Alzheimer’s Disease Psychosis Pending

2025-521757-16-00 Hallucinations and Delusions Associated with Alzheimer’ 4
A Phase 3 Study of Orelabrutinib in Non-active Secondary Progressive Multiple Sclerosis Pending

2025-524322-18-00 Non-active Secondary Progressive Multiple Sclerosis (SP 5
A Phase 3 Study of Orelabrutinib in Patients with Primary Progressive Multiple Sclerosis Recruiting

2025-524316-11-00 Primary Progressive Multiple Sclerosis (PPMS) 5 2026-06-11
Open-label Extension of KarXT + KarX-EC for Agitation in Alzheimer’s Disease Recruiting

2024-519994-20-00 Agitation Associated with Alzheimer’s Disease 5 2026-06-01
ACP-204 in Adults With Lewy Body Dementia Psychosis (LBDP) Recruiting

2025-521711-39-00 Lewy body Dementia psychosis (LBDP) 5 2026-05-17
A clinical trial to learn about the effects of VHB937 in people with Alzheimer's disease Recruiting

2024-516966-12-00 Alzheimer’s disease 4 2026-02-13
A Study of ML-007C-MA for the Treatment of Hallucinations and Delusions Associated with Alzheimer’s Disease Psychosis Recruiting

2024-519820-26-00 Hallucinations and Delusions Associated with Alzheimer’ 4 2026-01-22
ACP-204 in Adults With Lewy Body Dementia Psychosis (LBDP) Recruiting

2025-521710-25-00 Lewy Body Dementia Psychosis (LBDP) 4 2025-12-04
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated with Alzheimer’s Disease. Recruiting

2025-520612-34-00 Agitation Associated with Alzheimer’s Disease 5 2025-11-28
A study to assess the efficacy and safety of ITI-1284 in the treatment of Agitation Associated with Alzheimer's Dementia Recruiting

2024-514680-26-00 Agitation Associated with Alzheimer’s Dementia 4 2025-07-17
A study to assess the efficacy and safety of ITI-1284 in the treatment of Psychosis Associated with Alzheimer's Disease Recruiting

2024-513035-25-00 Psychosis associated with Alzheimer’s Disease 4 2025-07-11
A study of IPN10200 for the treatment of cervical dystonia in adults Recruiting

2024-519248-34-00 Cervical Dystonia 4 2025-06-17
This 52-week, open-label extension study is to evaluate the long-term safety and tolerability of ACP-204 in subjects with ADP. Recruiting

2023-507351-29-00 Alzheimer's Disease Psychosis 5 2024-12-03
A study to evaluate IPN10200 safety and efficacy in the prevention of episodic or chronic migraine in adults Ended

2024-511101-28-00 Episodic Migraine Chronic Migraine 4 2026-02-24
A Study to Evaluate the Efficacy, Safety, and Tolerability of Atogepant for the Preventive Treatment of Menstrual Migraine Ended

2024-512946-41-00 Menstrual Migraine 5 2025-03-05
ACP-204 in Adults with Alzheimer’s Disease Psychosis Ended

2023-507325-42-00 Alzheimer Disease psychosis 4 2024-07-02
A Phase 3 Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants with Early Alzhei… Ended

2023-508306-15-00 Alzheimer’s Disease 5 2024-06-26
Randomized, Double-Blind, Placebo-Controlled, Multiple-Attack Study with an Open-Label Extension to Evaluate the Efficacy, Safety, Tolerabil… Ended

2023-506029-12-00 Migraine 5 2024-04-03
A study to evaluate the effectiveness and safety of Dysport® for the prevention of episodic migraine in adults Ended

2023-504839-40-00 Episodic Migraine 5 2024-03-18
A Double-blind, Randomized, Active-controlled, Parallel-group, Phase 1/3 study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and S… Ended

2022-501622-37-00 Multiple Sclerosis 5 2024-01-16
Dose-response characterization of VER-01 in the treatment of patients with chronic non-specific low back pain Ended

2023-507358-34-00 For the treatment of patients with chronic non-specific 4 2024-02-13
Comparative Study of Oral Atogepant Versus Oral Topiramate to Assess Adverse Events and Disease Activity in Adult Participants With Migraine… Ended

2022-501172-25-00 Chronic and Episodic Migraine 5 2024-01-17
Phase 3 Open label clinical trial with oral Atogepant for the prevention of migraine Ended

2023-507096-21-00 Chronic or Episodic Migraine (Migraine without aura, mi 5 2021-08-16